摘要
新辅助治疗可以为病人带来与辅助治疗相似的临床获益。新辅助治疗能够降低肿瘤负荷,从而使手术范围缩小,手术创伤减小。研究肿瘤对新辅助治疗的反应性可以获得重要的预后信息,更好地了解残余肿瘤的生物学行为。乳腺癌新辅助治疗方案的选择、新辅助治疗后手术及放疗的决策是临床医师应掌握和重视的问题。对乳腺癌病人实施规范化的新辅助治疗将有助于提高生存获益。
Neoadjuvant chemotherapy provides clinicaloutcomes equivalent to those achieved from adjuvant setting.The therapeutic response to neoadjuvant treatment mayinclude a reduction in tumor burden that alleviates themorbidity associated with locoregional therapy. Importantprognostic information can be gained based on the response totreatment and knowing the quantity and biology of the residualdisease. Landmark trials and contemporary perspectives onneoadjuvant treatment regimens are the issues that surgeonsshould grasped and pay attention to. The standard neoadjuvantchemotherapy could improve the survival of patients withbreast cancer.
出处
《中国实用外科杂志》
CSCD
北大核心
2015年第7期709-713,共5页
Chinese Journal of Practical Surgery
关键词
乳腺癌
新辅助治疗
breast cancer
neoadjuvant treatment
